Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00139230 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck
A Phase 2 study of Squamous Cell Carcinoma and Carcinoma of Head/Neck, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 2
- Study locations
NCT00139230 is a Phase 2 study of Squamous Cell Carcinoma and Carcinoma of Head/Neck that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 30 participants, below the 103-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (71% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT00139230, a Phase 2 study of Squamous Cell Carcinoma and Carcinoma of Head/Neck, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to further test a combination chemotherapy regimen for the treatment of squamous cell carcinoma of the head and neck and to see if the addition of supportive medicine can help reduce the side effects of these drugs.
Conditions Studied
Interventions
- DRUG Cisplatin
- DRUG Leucovorin
- DRUG G-CSF
- DRUG 5-Fluorouracil
- DRUG Taxotere
Study Locations (2)
Massachusetts
- Massachusetts General Hospital - Boston
- Dana-Farber Cancer Institute - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1997-01 |
| Est. Completion | 2006-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00139230
The ClinicalTrials.gov registry entry for NCT00139230 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 103-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target (71% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Squamous Cell Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Cisplatin is the first listed.
NCT00139230 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00139230 about?
NCT00139230 is a clinical study titled "Combination Chemotherapy for Locally Advanced Squamous Cell Carcinoma of the Head and Neck". The purpose of this study is to further test a combination chemotherapy regimen for the treatment of squamous cell carcinoma of the head and neck and to see if the addition of supportive medicine can help reduce the side effects of these drugs.
What is the current status of trial NCT00139230?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 1997-01. Estimated completion is 2006-12.
What conditions does trial NCT00139230 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma, Carcinoma of Head/Neck.
What interventions are being tested in trial NCT00139230?
The interventions under investigation include: Cisplatin (DRUG), Leucovorin (DRUG), G-CSF (DRUG), 5-Fluorouracil (DRUG), Taxotere (DRUG).
Who is sponsoring clinical trial NCT00139230?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00139230 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma
RECRUITING · Phase 2
-
Impact of COL7A1 Gene Therapy on SCC Recurrence in RDEB Skin
RECRUITING · Phase 2
-
Toripalimab With Chemotherapy for Sinus Cancer
RECRUITING · Phase 2
-
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
RECRUITING · Phase 2
-
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
RECRUITING · Phase 2
-
Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.